A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Exclusion Criteria

• •History of life-threatening asthma or COPD that is defined for this protocol as an asthma or COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.
• •Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of Screening Visit.
• •Is being treated with a long-acting β2-agonist alone.
• •Is currently being treated with Ventolin HFA.
• •Any asthma or COPD exacerbation requiring oral corticosteroids within 2 months of Screening Visit. A subject must not have had any hospitalization for asthma or COPD within 4 months prior to Screening Visit.
• •Historical or current evidence of a clinically significant non-asthmatic acute or chronic condition.
• •Uncontrolled hypertension
• •History of any adverse reaction to any component of the HFA-MDI formulation.
• •Participation in any investigational drug study within the 30 days preceding the Screening Visit.